It takes guts to pick the campaign that had the most impact in research if it was polarizing. This is where a bold choice takes courage, and a plan for winning or learning.
A spate of recent investments suggests private equity firms may be rekindling their interest in the point-of-care media space, two years after a scandal sent some investors fleeing.
The back-and-forth over the Department of Health and Human Services rule requiring inclusion of list prices in TV drug ads had advertisers scrambling to file Form 2253 submissions to the FDA.
Price-disclosure whiplash highlights breakneck pace
